gallium-68 PNT6555

Gallium-68 PNT6555 is a radiopharmaceutical diagnostic agent designed for PET imaging of tumors that express fibroblast activation protein alpha (FAP). It consists of a FAP-targeting ligand (PNT6555) conjugated to a DOTA chelator, which is labeled with the positron-emitting radionuclide gallium-68. The drug selectively binds to FAP, which is overexpressed in cancer-associated fibroblasts within the tumor microenvironment of various solid tumors. This enables sensitive and specific imaging of FAP-positive cancers. Gallium-68 PNT6555 has demonstrated rapid clearance from normal tissues and prolonged retention in tumors in preclinical models, supporting its use as an imaging companion to therapeutic radioligands such as lutetium-177 PNT6555. The primary developer is POINT Biopharma, and it is being evaluated primarily for use in oncology indications including colorectal cancer, pancreatic ductal adenocarcinoma, esophageal carcinoma, melanoma, bile duct neoplasms, and soft tissue sarcoma[1][2][3][4][6][7].